A Phase 1/2 Multicenter Open-Label Study to Evaluate the Safety Tolerability and Preliminary Antitumor Activity of TNG462 in Combination with Other Agents in Patients with Pancreatic or Non-Small Cell Lung Cancer with MTAP Loss and RAS Mutation
Brief description of study
This Phase 1/2 study will determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236 or RMC-9805. Overall, the study comprises a dose escalation phase and a dose expansion phase.
Clinical Study Identifier: s25-00454
ClinicalTrials.gov Identifier: NCT06922591
Principal Investigator:
Kristen Spencer.
Other Investigators:
Anam Qureshi,
Elaine Shum,
Yoke Wah Khoo,
Kirby Rodriguez,
Manuel Hidalgo Medina,
Maya Dimitrova,
Mariam M Cheaib,
Salman Rafi Punekar,
Jonathan B Kahn,
Janice Mehnert,
Joshua K Sabari,
Keriann M Scavone,
Nina Beri,
Rajwanth Veluswamy,
Paul E. Oberstein,
Eneil De La Pena,
Kathleen M Lutz,
David R. Wise,
Jessica Wang,
Michelle Diane Swanson Lightfoot,
Carol M Lee,
Paige Gugerty,
Zujun Li,
Samantha VanMaanen,
Rafael Winograd,
Maria Francis,
Gabrielle Fridman,
Kathleen M Madden,
Nancy Chan,
Bhavana Pothuri,
Ruth A White,
Matthew A. Ingham,
Douglas K Marks.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
